Last reviewed · How we verify
BPI-9016M
At a glance
| Generic name | BPI-9016M |
|---|---|
| Also known as | No other name so far, No other name currently |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors (PHASE1)
- Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPI-9016M CI brief — competitive landscape report
- BPI-9016M updates RSS · CI watch RSS
- Betta Pharmaceuticals Co., Ltd. portfolio CI